High Grade (G3) Neuroendocrine Neoplasms Should Be Further Classified According to Morphological Differentiation Abstract #920

Introduction: Neuroendocrine neoplasms (NENs) with a Ki-67 >20% (Grade 3) are classified together as Neuroendocrine Carcinomas (NEC), and are usually considered as poorly differentiated. However Grade (G)3 NENs may be heterogeneous, with some demonstrating a well-differentiated cell morphology.
Aim(s): To compare well-differentiated tumors (G3 WD-NETs) to poorly differentiated carcinomas (G3 PD-NECs).
Materials and methods: All G3 NENs referred between 2008 and 2013 were identified from a histopathology database. Clinical data analysed included Ki-67, imaging, response to treatment and overall survival (OS).
Conference: 11th Annual ENETS Conference (2014)
Category: ...none of the below
Presenting Author: Dr Dalvinder Mandair
Keywords: Ki-67, g3 NENs

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2248 High Grade (G3) Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Should the New WHO Classification Apply to All?
Introduction: Grade 3 (G3) neuroendocrine neoplasms (NEN), arising from the gastro-entero-pancreatic system (GEP), are classified according to WHO 2010 and defined as having a Ki67 of > 20%. However this groups together G3 well differentiated neuroendocrine tumours (WD-NET) with poorly differentiated neuroendocrine carcinomas (PD-NEC). Recently, WHO have proposed a new classification for pancreatic NEN, with sub-division into G3 WD-NET and G3 PD-NEC
Conference: 15th Annual ENETS conference (2018)
Category: Pathology - grading, staging
Presenting Author: Dr Dalvinder Mandair
Authors: Furnace M, Muller G, Rundell C, Shah R, ...
#2175 A Retrospective Analysis of 344 Cases with Neuroendocrine Neoplasms
Introduction: Ki-67 is a nuclear protein that is strictly associated with cellular proliferation,acting as a cellular marker for proliferation in clinical practice to determine the degree to which the tumor cells are duplicating. Ki-67 index strongly ties to the prognosis and provides guiding significance to clinical decisions.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Zheng Liu
Authors: Liu Z, Zhao H, Wu Y, Jiang L, ...
#845 Ki-67 Index as a Biomarker of Response to Cytotoxic Chemotherapy
Introduction: Chemotherapy (CT) is widely used for neuroendocrine tumors (NET) but there are no validated biomarkers to predict response. The Ki-67 proliferation index has been proposed as a means of selecting patients for CT but robust data are lacking.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Alexa Childs
Authors: Childs A, Kirkwood A, Lee A, Caplin M, ...
Keywords: chemotherapy, Ki-67
#1396 3-Drugs Chemotherapy Regimen for G3 PanNENs with Ki67 below 55%: Single Institution Experience
Introduction: To date no standard regimen of chemotherapy (CTH) is universally approved for advanced pancreatic neuroendocrine neoplasms (PanNENs) with Ki67<55% and no predictive selection criteria is available.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Elisabetta Grego
#1405 Capecitabine-Temozolomide in G3 Neuroendocrine Neoplasms
Introduction: There is no standard second line treatment for G3 neuroendocrine neoplasms (NENs). The sensitivity to platinum combinations of G3 NENs with a Ki67 < 50% remains unclear.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Guillermo Crespo Herrero